Technologies optimizing monoclonal antibodies to restore immune disorders

  • During preclinical development, FR104 was included in a global option and license agreement with Janssen Biotech (Johnson & Johnson Group). This option has been exercised in July 2016 to continue clinical development of this compound (View Partnerships).
  • The Phase 1 clinical trial with FR104 is now completed and has shown positive results, and applications are expected in rheumatoid arthritis and transplantation.

FR104, an optimized monoclonal antibody fragment targeting the CD28 receptor

FR104 is a monoclonal antibody fragment, selected and optimized to target the CD28 receptor, a key receptor in effector T lymphocytes. FR104 specifically blocks the destructive function of effector T lymphocytes without blocking the regulation function of regulator T lymphocytes, thus fostering immuno-tolerance in autoimmune diseases and transplantation.

The binding of CD28, expressed on the surface of a T lymphocyte, with its B7-1 (also called CD80) or B7-2 (also called CD86) ligands expressed on the surface of an antigen-presenting cell, provides the lymphocyte with the necessary signal to its complete activation: this is a co-stimulatory signal. Co-stimulatory signals regulate lymphocyte responses. The pharmacological action of this co-stimulatory signal represents a new therapeutic pathway to regulate the immune response, in order to fight autoimmune reactions with the decrease of adverse immune responses and to avoid transplant rejection.